5-(2-fluorophenyl)-1H-pyrrole-3-carbonitrile NEW

‌Vonoprazan Fumarate Intermediate (CAS 1240948-77-9)‌
Google Keywords: Vonoprazan Intermediate, CAS 1240948-77-9, Gastrointestinal Drug Synthesis, P-CAB API Manufacturing, GMP Pharmaceutical Intermediates

🌟 ‌Product Overview‌

‌Vonoprazan Fumarate Intermediate‌ (CAS 1240948-77-9) is a critical high-purity chemical intermediate used in synthesizing ‌Vonoprazan Fumarate‌, a potassium-competitive acid blocker (P-CAB) approved for treating acid-related gastrointestinal disorders, including gastric ulcers and reflux esophagitis. This intermediate ensures precise and scalable production of the API, aligning with global pharmaceutical quality standards.

• ‌Primary Function‌: Key building block for Vonoprazan Fumarate API synthesis, enabling robust and selective chemical transformations.

• ‌Applications‌: Gastrointestinal drug development, acid suppression therapies, and large-scale API manufacturing.

✅ ‌Key Advantages‌

🔹 ‌Ultra-High Purity‌ | ≥99.5% (HPLC/GC verified) | Complies with ICH Q11 guidelines for pharmaceutical intermediates.
🔹 ‌Scalable Process‌ | Optimized for high-yield synthesis (>85% efficiency) with minimal byproducts, reducing production costs.
🔹 ‌Regulatory Ready‌ | Fully characterized (NMR, HRMS, FTIR) to support FDA/EMA filings and GMP compliance.

🧪 ‌Applications‌

1. ‌API Manufacturing‌: Enables efficient synthesis of Vonoprazan Fumarate with consistent batch-to-batch quality.

2. ‌Process Development‌: Accelerates R&D for optimizing synthetic routes and enhancing production sustainability.

3. ‌Quality Assurance‌: Used in analytical method validation and stability testing during API release.

📜 ‌Quality Assurance‌

• ‌Testing Methods‌: HPLC, GC, NMR, HRMS, and FTIR for structural verification and impurity profiling.

• ‌Standards‌: Meets USP <1086>, EP 10.0, and ISO 9001:2015 certified production protocols.

📈 ‌Market Trends‌

The ‌global acid-related disorder treatment market‌ is projected to reach ‌$6.8 billion by 2030‌ (CAGR 4.9%), driven by rising prevalence of GERD and demand for fast-acting therapies like Vonoprazan. This intermediate supports rapid scaling of P-CAB drug production to meet global healthcare needs.

Power your gastrointestinal drug pipeline with Vonoprazan Fumarate Intermediate – precision-engineered for purity, scalability, and compliance.